Caring for lifer and health Making contributions to the health of human beings
Recently, the 2026 Frontier Forum on Innovative Cancer Treatments was successfully held in the Boao Lecheng Intern
Jinrui recently attended the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, where members of the company s team met with biotechnology and pharmaceutical industry representatives from North America, Europe, and Asia
An important study titled "Liposomal Honokiol Inhibits Non-Small Cell Lung Cancer Progression and Enhances PD-1 Blockade via Suppressing M2 Macrophages Polarization " was published in the internationally renowned journal Phytomedicine in December 2024
Beijing Jinrui Jiyie Medical Technology Co , Ltd recently published a significant research paper titled "Integrated Network Pharmacology, Bioinformatics, and Experimental Approach to Explore the Mechanism of Honokiol Liposomes Against Glioblastoma "
November 18, 2024(EST), Jinrui Foundation Biotech Co , Ltd announced that its globally first-in-class drug, JRF101